To evaluate the role of hMena overexpression in MAPK and AKT activation, we categorized in hMena negative (score 0/1) and hMena positive (score 2/3) 60 HER2 positive and 118 HER2 negative primary BC of 178 cases analyzed. The gene discussed is AKT1; the disease is breast cancer.